Epstein-Barr virus infection in renal transplant recipients. Effects of antithymocyte globulin and interferon.
We studied Epstein-Barr (EB) virus excretion and antibody in 41 renal transplant recipients enrolled in a placebo-controlled trial of human leukocyte interferon. Half the patients were also treated with antithymocyte globulin. Epstein-Barr virus excretion occurred more often in recipients of cadaver kidneys (P = 0.03) and those receiving antithymocyte globulin (P = 0.04) and less often in patients given interferon (P = 0.08). Antibody to viral capsid antigen increased fourfold or more in 12 of 22 patients treated with antithymocyte globulin and in none of the non-antithymocyte globulin-treated group (P = 0.0002). Antibody to the restricted component of early antigen rose fourfold or more in eight patients and appeared related to the occurrence of syndromes similar to those attributed to cytomegalovirus in transplant recipients. We conclude that increasing immunosuppression augments the rate of EB virus reactivation and that EB virus may be an important pathogen in heretofore ill-defined syndromes.
D000914:Antibodies, Viral / Q000032:analysis; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D002102:Cadaver; D002986:Clinical Trials as Topic; D004854:Herpesvirus 4, Human / Q000276:immunology / Q000302:isolation & purification*; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D007372:Interferons / Q000627:therapeutic use*; D016030:Kidney Transplantation; D010919:Placebos; D013601:T-Lymphocytes / Q000276:immunology*; D014184:Transplantation, Homologous; D014766:Viremia / Q000209:etiology
D000914:Antibodies, Viral; D000961:Antilymphocyte Serum; D010919:Placebos; D007372:Interferons